Endogenous NMDA agonist and transmitter candidate. May distinguish between NMDA receptor subtypes.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 167.12. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.98 mL||29.92 mL||59.84 mL|
|5 mM||1.2 mL||5.98 mL||11.97 mL|
|10 mM||0.6 mL||2.99 mL||5.98 mL|
|50 mM||0.12 mL||0.6 mL||1.2 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Monaghan and Beaton (1991) Quinolinate differentiates between forebrain and cerebellar NMDA receptors. Eur.J.Pharmacol. 194 123 PMID: 1676371
Prada de Carvalho et al (1996) The endogenous agonist quinolinic acid and the non-endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem.Int. 28 445 PMID: 8740453
Stone and Burton (1988) NMDA receptors and ligands in the vertebrate CNS. Prog.Neurobiol. 30 333 PMID: 2830636
Stone and Perkins (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in the rat CNS. Eur.J.Pharmacol. 72 411 PMID: 6268428
If you know of a relevant reference for Quinolinic acid, please let us know.
View Related Products by Product Action
Keywords: agonists Transmitter candidate Glutamate NMDA Receptors N-Methyl-D-Aspartate iGluR Ionotropic NMDA Receptors
1 Citation for Quinolinic acid
Citations are publications that use Tocris products. Selected citations for Quinolinic acid include:
Tsutsui-Kimura et al (2015) Milnacipran remediates impulsive deficits in rats with lesions of the ventromedial prefrontal cortex. Nat Commun 18 PMID: 25522418
Do you know of a great paper that uses Quinolinic acid from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.